| suiis­º­¶ | ³]¬°­º­¶ | ¥[¤J³Ì·R
­­®É¯S»ù°Ó«~
» §ó¦h
 
²{¦b¦ì¸m¡Gsuiis±MÄæ / ÃöÃh¥Í©R¨ó·| ªº±MÄæ / ¹êÅç°Êª«´À¥N¦p¦ó¹ê²{¡H

ÃöÃh¥Í©R¨ó·| ªº±MÄæ

¹êÅç°Êª«´À¥N¦p¦ó¹ê²{¡H
2018/10/03
ÂI¾\²v¡G904

§@ªÌ¡G°ê¥ß»OÆW¤j¾Ç°Êª«¬ì¾Ç§Þ³N¾Ç¨t¡@®}ÀÙ®õ±Ð±Â

«e¨¥

¹êÅç°Êª«³Q¨Ï¥Î©ó¬ì¾ÇÀ³¥Îªº¥Î³~ºØÃþÁc¦h¡A¦ý¬O¥i¥H²²¤°Ï¤À¬°¬ã¨s¡B°Ó«~ÀËÅç¡B¥Í²£¡B±Ð¾Çµ¥¥|¤jÃþ§O¡C¤£½×¬O¶i¦æ¨º¤@¤è­±ªº¬ì¾ÇÀ³¥Î¡A§Ú­Ì¥²¶··NÃѨì°Êª«¬O·|·P¨ü¨ì¯kµh¡BµJ¼{»P®£Äߪº¡C§Y¨Ï¨S¦³¶i¦æ¹êÅç¡A´N³s³Ì²³æªº§ó´«¹}¨|²°¾Þ§@¡A´N·|Åý¤j¹«¤ß¸õ³t²v´£°ª20-46%¡A¦åÀ£¤W¤É15-34%¡CÃZ¡BÙʳ¾¡BÀn¡B¥ÀÂû¡B³Â³¶¡A¥u­n°Ê¨ì¥L­Ì¡A¦å¤¤¥Ö½èà¬(ºò­¢«ü¼Ð¶Pº¸»X)¿@«×´N¤W¤É100-730% (Balcombe et al., 2004)¡C¤@¯ë²ß¥H¬°±`ªºÂ²³æ¹êÅç¾Þ§@¡A¤]·|¹ï°Êª«³y¦¨·¥¤jªºÀ£¤O¡C¨Ò¦p¡A¤p¹«¶i¦æ§À¦y±Ä¦å¡A¦å¤¤¥Ö½èି@«×¤W¤É595%¡C¤j¹«¶i¦æºÞÁý¡A¦å¤¤¥Ö½èି@«×³Ì°ª¥i¤W¤É596%(Balcombe et al., 2004)¡C

¹êÅç°Êª«¨Ï¥Î©ó¬ã¨sªº´À¥N¤è®×

¡@¡@¦b½Í°Êª«¨Ï¥Î©ó¬ã¨sªº¦X²z©Ê¡A¦³¥²­n¥ý±j½Õ°Êª«¸ÕÅ礣¬O¸U¯àªº¡C¨Ò¦p￾¦Ãþ¹êÅç°Êª«¬O¤£¬O³Ì²z·Qªº¤HÃþ¯e¯f°Êª«¼Ò¦¡¡A±`±`¬O³Q´£¥X¨Ó°Q½×ªºÄ³ÃD¡C¥D­n­«ÂI¬O￾¦Ãþ¬O¸ò¤HÃþ¬O¦³°ò¦]ªí²{¥H¤Î¥Í²z¥\¯àªº®t²§©Ê¦s¦b¡C¨Ò¦p¡A¤p¹«¦å²Gªº§K¬Ì²Ó­M¥D­n¬O¥Ñ70-90%²O¤Ú²y»P10-30%¶Ý¤¤©Ê²y©Ò²Õ¦¨¡A¤HÃþ«h¬O30-50%²O¤Ú²y»P50-70%¶Ý¤¤©Ê²y©Ò²Õ¦¨¡A³o¨Ç·|³y¦¨¤p¹«ªº¤p¸zµoª¢¤ÏÀ³¸ò¤HÃþ¦³©Ò¤£¦P¡C¤p¹«ªº¤p¸zÂH½¤²O¤Ú¸¢Å骺B²O¤Ú²y²Õ¦¨¸ò¤HÃþ¤£¦P¡A¤p¹«ªºB²O¤Ú²y¨ã³Æªº°»´ú¯f­ìµß§Ü­ìªº¨üÅé¸ò¤HÃþ¤£¦P¡A¤p¹«ªºB²O¤Ú²y²£¥Íªº§ÜÅéIgAªº«¬ºA»P¹B§@¾÷¨î¸ò¤HÃþ¤£¦P¡C¤p¹«¸ò¤HÃþ¸z¹D²Óµß¬ÛÁöµM³£¥HFirmicutes »PBacteroidetes¨â¤jªù¬°¥D¡A¦ý¥J²Ó±´¨s¨ä²Ó³¡ªºµßºØ²Õ¦¨«o¦³«Ü¤j®t²§¡A¦Ó¥B¤p¹«¦³§]­¹¦Û¨­ÁT«Kªº²ß©Ê¡A³y´N¤p¹«ªºµß¬Û²Õ¦¨»Pµß¬Ûºû«ù¤è¦¡¸ò¤HÃþ¦³«Ü¤j®t²§(Gibbons and Spencer, 2011)¡CÁöµM¥H¤p¹«¬°¼Ò¦¡¶i¦æªº¸z¹D¯e¯fªvÀø¥H¤Î¯q¥Íµßªº¾ã¸z®ÄªGªº¬ã¨s«D±`Ác¦h¡A¦ý¬O¦³¦h¤Ö¥i¥H¯u¥¿À³¥Î¨ì¤HÃþ¨­¤W¡H

Akhtar ( 2015) ¦CÁ|¹L¥h¨Ï¥Î¤p¹«¹êÅç¼Ò¦¡¶i¦æ¤¤­·¡B°Ê¯ßµ°¼Ëµw¤Æ¡BÀù¯g¡B¦Ù¦×µäÁY©Ê¯áÅè°¼¯Áµw¤Æ¯g¡B¸£³¡³Ð¶Ë¡B°h¤Æ©Ê¥¢´¼¯g¡Bµoª¢¤ÏÀ³µ¥ÂåÃĬã¨s¡A¨ì¤HÃþ¨­¤W«o¬OµL®Äªº¨Ò¤l¡C¨ÃÁ|¨ÒFDA©ó2004¦~¦ô­p¡A³q¹LÁ{§É«e¸ÕÅ窺Ãľ¯¡A¦³92%µLªk¹F¦¨¤W¥«ªº³Ì«á¶¥¬q¡CHartung (2013)Á|¥X§ó·sªº²Î­p¸ê®ÆÅã¥Ü¡A§Y¨Ï¦³Á{§É«eªº°Êª«¹êÅç¡A¤´µM¦³95%Ãľ¯µLªk¹F¦¨¤W¥«ªº³Ì«á¶¥¬q¡CÅãµM°Êª«¹êÅ窺¦³®Ä©Ê¸g¹L¦h¦~ÁÙ¬O¨S¦³§ï¶i¡A§Ú­Ì»Ý­n¤Ï¬Ù¬O¤£¬O¦]¬°¬Y¤@ª«ºØ¼Æ¶q¦h¡B»ù®æ§C¥H¤Î"®e©ö"¨Ï¥Î¡A¦]¦Ó§Y¨Ï¦³92-95%ªº¥¢±Ñ²v¡A¤]µL©Ò¿×?

¦pªG¡A¬ì¾Ç¬É¯à¦h¦h¬ãµo´À¥N¤è®×¡A¨Ã¥BÁ׶}©Î¸Ñ¨MµL®Ä°Êª«¹êÅç¡A¬Û«H¤£¶È¦³§U©ó´î¤Ö¬¡Åé°Êª«ªº¨Ï¥Î¡A¦³§U©ó´£¤É¬ì¾Ç¬ã¨sªí²{¡A§ó¦³§U©ó¬°¤HÃþ¯e¯f§ó§Ö³t¦³®Ä§ä¨ì¸Ñ¤è¡CÂåÃĪº¶}µo¬ã¨s¹Lµ{¤¤¡A¬r©Ê¸ÕÅç¬O«D±`­«­nªº¤@Àô¡A¦ý¬OÅj¾¦Ãþ¯à°÷¦¨¥\¹w´ú¤HÃþ¬r©Ê¤ÏÀ³ªº¾÷²v¥u¦³43%¡A«DÅj¾¦Ãþ°Êª«ªº¦¨¥\²v¸û°ª¦ý¤]¥u¦³63% (Olson et al., 2000)¡C§Y¨Ï¬O»P¤HÃþ°ò¦]°ª«×¬Ûªñªº·áµUÃþ´ú¸Õ¡A¦¨¥\²vÁÙ»·§C©ó¤j¹«»P¤p¹«©¼¦¹¶¡ªº¹w´ú(Bailey et al., 2015)¡C©Ò¥H¡A°Êª«¹êÅ窺¯Ê¥¢¬O¤£®e©¿µøªº¡C

¹L¥h³\¦h¦~¨Ó¡A¬ì¾Ç¬É¤w¸g²Ö¿n³\¦h¤HÃþ»P¤p¹«ªº°ò¦]¥H¤Î¯e¯f¬ã¨s¡A²{¦b¤w¸g¦³¬ã¨s¹Î¶¤¶}©l¹Á¸Õ±q¦UºØ¸ê®Æ®w¡A±N¹L¥h²Ö¿nªº¸ê®Æ¶°¦X°_¨Óµo®iµêÀÀ¤HÅé¥H¤ÎµêÀÀ¤p¹«ªº¹q¸£¼Ò¦¡(Land et al., 2013)¡C§Ú­Ì¥i¥H¥ý¦b¹q¸£¸Ì¶i¦æ¦UºØµêÀÀ´ú¸Õ¡A§ä¨ì³Ì¥i¦æªº½Õ±±¤è®×¡A¦A¥h¶i¦æ°Êª«¹êÅç¥[¥HÅçÃÒ¡A³o¼Ë¥i¥H§K°£³\³\¦h¦hªº¬¡Åé°Êª««e¸m¹êÅç¡A¤]¥i¥H¥ý¦æ¤ñ¸û¤HÃþ»P¤p¹«°ò¦]½Õ±±»P¥Í²z¤ÏÀ³ªº²§¦P¡A§K°£³\³\¦h¦hªº²q´ú»P¿ù»~±À½×¡C

¥Î©ó³]­pÃÄ«~µ²ºcªº¹q¸£¼Ò¦¡(Quantitative Structure Activity Relationship; QSAR)¤]¬O«Ü¦nªº¤u¨ã¡A§Q¥Î¤À¤lµ²ºc©M¬r©ÊªºÃö«Y¥h¼ÒÀÀÃĪ«ªº¬r©Ê©M®Ä¤O¡AÁקK¥­¥ÕÄ묹°Êª«¡A¤]¥i¥H¸`¬Ù¬ã¨s¸ê·½¡AÁקK¿ù»~ªº¬ã¨s¤è¦V¡C«¢¦ò¤j¾ÇªºWyss Institute ¶}µo¥X´¹¤ù¥d§X¦¡¤H¤uªÍŦ²Õ´©Î¤H¤u¸z¹D²Õ´¡A¼ÒÀÀ¥¿±`ªÍŦ¥\¯à©Î¸z¹D¥\¯à¡A³o¼Ëªº¤u¨ã´N¬Û·í¤è«K¶i¦æ¦UÃþÃĪ«¹êÅç¡A¤£¥Îª½±µ¨Ï¥Î¬¡Åé°Êª«¶i¦æ¹êÅç¡C±d¤Dº¸¤j¾Çªº¬ã¨sªÌ¤]¦³±N¤QºØ²Õ´ªº²Ó­M¤À§O©ñ¤J´¹¤ù¥d§X¦¡ªº¤Q­Ó¤p«Ç¡A¥i¥H¦P®É´ú¸Õ¤QºØ²Õ´²Ó­M¹ï¦PºØÃĪ«ªº¤ÏÀ³(Dance, 2015)¡CÅé¥~²Ó­M°ö¾i¤]¥i¥H°µ¨ì3D¥ßÅé²Õ´¼Ò¦¡¡A§ó±µªñ¬¡Åé°Êª«ªº¹ê»Ú±¡ªp(Fatehullah et al., 2016)¡C°ê¥~¦³³\¦h´À¥N¤è®×¬ãµo±À¼sªº¸ê°T¤¤¤ß(http://www.piscltd.org.uk/ links-resources/http://alttox.org/resource-center/databases/http://alttox.org/ resource-center/organizations-associations/)¡A¦¬¶°¦UºØ¹êÅç°Êª«ªº´À¥N¤è®×¨Ñ¦U¬É°Ñ¦Ò¨Ï¥Î¡C

¹êÅç°Êª«¨Ï¥Î©óÀËÅ窺´À¥N¤è®×

¤ÆùÛ«~(cosmetics)¥]§t¤ú»I¡BªÎ¨m¡B¬~¾vºë¡B°£¦½¯ä¾¯¡B­»¤ô¡B¬ü§©¥Î«~¡A¬°¤F¦b¼Ú·ù¦U­Ó·|­û°ê®a¦³²Î¤@ªººÞ²z«ü¤Þ¡A¼Ú·ù²z¨Æ·|¦b1976¦~­q©w¤F²Ä¤@­Ó¤ÆùÛ«~ºÞ²z«ü¤Þ¡A©ú½T±N¤ÆùÛ«~»PÂåÀø¥Î«~¥H¤Î·|¼L¤Ú¦Y¶i¡B»ó¤l§l¤J¡Bª`®g¡B®I´Ó¶i¤HÅ骺²£«~§@°Ï¤À¡A¨Ã¥B©ú©w¸T¤î²K¥[ª«½è(The Council of the European Communities, 1976 )¡C¦]¬°¤ÆùÛ«~¦b¨Ï¥Î¤W·|±µÄ²§Ú­Ìªº¥Ö½§©Î¤fµÄ¡A¬°¤F½T«O¦w¥þ¡A¹L¥h¦b¶i¦æ«~½èÀËÅç®É­Ô³£·|¦³¬¡Åé°Êª«´ú¸Õªºªk³W­n¨D¡A¥]§t¤fµÄ«æ¬r©Ê¡B¥Ö½§»P²´·ú«æ¬r©Ê´ú¸Õ¡A«Øij¨Ï¥Îªº¹êÅç°Êª«¥]§t¤j¹«»P¥Õ¤ò¦â¨ß¤l(The Council of the European Communities, 1984 )¡C°ò©ó«OÅ@¹êÅç°Êª«ªº­ì«h¡A¼Ú·ù²z¨Æ·|¤]´£¥X«ü¤Þ­n¨D¦pªG¦³´À¥N¤è®×¡A´N­n§K°£¨Ï¥Î¹êÅç°Êª«ªº¨Ï¥Î(The Council of the European Communities, 1986 )¡C

¦]À³§K°£¹êÅç°Êª«¨Ï¥Îªº«ü¤Þ±ø¤å¡A¼Ú·ù²z¨Æ·|¦b1993¦~´£¥X¹ï1976¦~«ü¤Þªº­×¥¿®×¡A­n¨D¦b1998¦~¯à°÷§¹¦¨¤£¨Ï¥Î¹êÅç°Êª«©ó¤ÆùÛ«~ÀË´ú(The Council of the European Communities, 1993 )¡C¦ý¬O¨ì¤F1997¦~¡A¤´µM¨S¦³¥i¦æªº´À¥N¤è®×¡A¦]¦¹®i©µ´Á­­¨ì2000¦~¡C¨ì2000¦~¡A¤S®i©µ´Á­­¨ì2002¦~¡C¼Ú¬wij·|¦b2003¦~´£¥X¹ï1976¦~«ü¤Þªº²Ä7¦¸­×¥¿®×¡A­n¨D¦b2013¦~¯à°÷¹F¦¨¼o¤î¤ÆùÛ«~­ì®Æ»P¦¨«~ªº°Êª«´ú¸Õ¡A¥H¤Î¸T¤î¨Ï¥Î°Êª«´ú¸Õªº¤ÆùÛ«~­ì®Æ»P¦¨«~¦b¼Ú·ù¦a°Ï¶i¦æ³c°â(The European Parliament and the Council of the European Union, 2003)¡C¼Ú¬wij·|¦b2009¦~¨M©w´£°ªªk«ß¦ì¶¥¡A´£¥X¤ÆùÛ«~ªk³W(The European Parliament and the Council of the European Union, 2009) ¨ú¥N¹L¥hªº1976¦~«ü¤Þ¥H¤Î¨ä©Ò¦³¾ú¦~­×¥¿®×¡C

¬°¤FÂÔ·V°_¨£¡A¼Ú·ù²z¨Æ·|Áܶ°±M®a¹ï¤ÆùÛ«~ÀËÅ窺°Êª«¸ÕÅç´À¥N¤è®×¤§¥i¦æ©Ê¡A±q¬rª«°Ê¤O¾Ç(Toxicokinetics)¡B¥Ö½§­P±Ó©Ê(Skin sensitization)¡B­«½Æ¾¯¶q¬r©Ê(Repeated dose toxicity)¡B­PÀù©Ê(Carcinogenicity)¡BÁc´Þ¬r©Ê(Reproductive toxicity)µ¥¤­ÃþÀËÅç¶i¦æµû¦ô(Adler et al., 2011)¡C

±M®a¤À²Õ·|ijªºµ²½×¬O¬rª«°Ê¤O¾Ç¤è­±ÁٯʤֵÇŦ»PÁx²G±Æ¥X¥H¤ÎªÍŦ§l¦¬ªº¥i¦æ´À¥N¤è®×¡A¹w­pÁٻݭn5-7¦~®É¶¡¶}µo¡C¥Ö½§­P±Ó©Ê¤è­±¡A¦]¬°»Ý­n­«½Æ¼ÉÅS©ó¨ë¿E·½¤~¯à¬Ý¨ì¤ÏÀ³¡A¤w¦³ªº´À¥N¤è®×¨S¿ìªk¶i¦æ¨ë¿E·½­«½Æ¼ÉÅS¸ÕÅç¡A³Ì¼ÖÆ[¹w­pÁٻݭn7-9¦~®É¶¡¶}µo¡C­«½Æ¾¯¶q¬r©Ê¤è­±¡A½T©w¦b2013¦~¤£¥i¯à¦³¥i¦æªº´À¥N¤è®×¥X²{¡A¦Ü©ó¬Æ»ò®É­Ô¥i¥H¦³¬ÛÃö§Þ³N¡A±M®aµLªk¹w¦ô¡C­PÀù©Ê¤è­±¡A³Ì¦nªºµû¦ô¤èªk¬O2¦~Åj¾¦Ãþ¹}¾i¸ÕÅç¡A¦ý¬O¥Ø«e¤@¯ë¬O±Ä¥Î¸ÕºÞ¸ÕÅçµ²¦X90¤Ñ¹}¾i¬r©Ê¸ÕÅç¨ÓÁYµuÀËÅç®Éµ{¡A90¤Ñªº°Êª«¹}¾i¸ÕÅç½T©w¦b2013¦~¤£¥i¯à¦³¥i¦æªº´À¥N¤è®×¥X²{¡A¬Æ»ò®É­Ô¥i¥H¦³¬ÛÃö§Þ³N¡A±M®aµLªk¹w¦ô¡CÁc´Þ¬r©Ê¤è­±¡A¥Ø«e¥u¦³°Êª«¸ÕÅç¥i¨Ï¥Î¡A¹w­pÁٻݭn¶W¹L10¦~®É¶¡¶}µo´À¥N¤è®×¡C

¼Ú¬w(°õ¦æ)©e­û·|¸ò¼Ú¬wij·|»P¼Ú·ù²z¨Æ·|·¾³q¬ö¿ý«ü¥X¡A¼Ú·ù²Õ´¤F¸Ñ¨ì¤F2013¦~¤´µM¨S¦³§¹µ½¥þ®Mªº¤ÆùÛ«~ÀËÅ窺°Êª«¸ÕÅç´À¥N¤è®×¥i¨Ï¥Î¡A¥u¦³³¡¤À´À¥N¤è®×¥i¦æ¡A¦ý¬O°ò©ó¯S®í¬Fµ¦¦Ò¶q¡A¼Ú·ù²Õ´¤´µM¨M©w¤£¦A®i©µ2013¦~¼o¤î¤ÆùÛ«~­ì®Æ»P¦¨«~ªº°Êª«´ú¸Õ¡A¥H¤Î¸T¤î¨Ï¥Î°Êª«´ú¸Õªº¤ÆùÛ«~­ì®Æ»P¦¨«~¦b¼Ú·ù¦a°Ï³c°â¤§³W©w(European Commission, 2013)¡C«áÄò¡A¼Ú¬w(°õ¦æ)©e­û·|¹ï¼Ú¬wij·|»P¼Ú·ù²z¨Æ·|³ø§i«ü¥X¡AºI¦Ü2015¦~¤´µM¨S¦³§¹µ½ªº¤ÆùÛ«~ÀËÅ窺°Êª«¸ÕÅç´À¥N¤è®×¥i¨Ï¥Î¡A¥i¥Îªº´À¥N¤è®×¬O¥Ñ¼Ú·ù°Êª«¸ÕÅç´À¥N¤è®×°Ñ¤ñ¹êÅç«Ç(European Union Reference Laboratory for Alternatives to Animal Testing, Directorate General Joint Research Centre of the European Commission; EURL ECVAM)­t³dÅçÃÒ»P¤½§i(European Commission, 2016)¡CEURL ECVAMªñ´Á¦~«×³ø§i©Ò¤½§i³q¹Lªº°Êª«¸ÕÅç´À¥N¤è®×¡A¥]§t3ºØ¥Ö½§«I»k´ú¸Õ¤èªk(Dermal Corrosivity Test Method)¡B1ºØ¥Ö½§¨ë¿E´ú¸Õ¤èªk(Dermal Irritation Test Method)¡B7ºØ²´·ú¬r©Ê´ú¸Õ¤èªk(Ocular Toxicity Test Method)¡B8ºØ±µÄ²©Ê¥Ö½§¹L±Ó´ú¸Õ¤èªk(Allergic Contact Dermatitis Test Method)¡B3ºØ«æ¬r©Ê´ú¸Õ¤èªk(Acute Toxicity Test Method)¡B3ºØ¿ò¶Ç¬r©Ê(Genetic Toxicity Test Method)¡B1ºØ­PÀù©Ê(Carcinogenicity Test Method)¡C¨ä¤¤²´·ú¬r©Ê´ú¸Õ¤èªk¥]§t¨Ï¥Î±O®_³õ·sÂA¤û²´²y»PÂû²´²y¬°´À¥N§÷®Æªº¤èªk¡A«æ¬r©Ê´ú¸Õ¤èªk¥]§t¨Ï¥Î´³°¨³½­F­Lªº¤èªk(EURL ECVAM, 2015)¡CEURL ECVAMªººô¯¸(https://eurl-ecvam.jrc.ec.europa.eu/)¡AÀH®É¨Ñ¦U¬É¬d¸ß¦UºØ¤w¸g³q¹LÅçÃÒ¥H¤Î¥¿¦b¶i¦æÅçÃÒªº°Êª«¸ÕÅç´À¥N¤è®×¡A¥H¤Î¤@¨Ç¥¿¦b¶i¦æ¬ãµoªº°Êª«¸ÕÅç´À¥N¬ã¨s®×¡C

¦]¬°¥Ø«eÁÙ¨S¦³§¹¾ãªº¦UºØÃþ§Oªº´À¥N¤è®×¥i¥H±Ä¥Î¡A©Ò¥H¹³¼Ú·ù¦a°Ï±Ä¨ú¬Fµ¦©Ê¾É¦Vªºªk³W±j¨îºÞ±±¤ÆùÛ«~­ì®Æ»P¦¨«~¡A³o¦ÛµM·|­­¨î¨ì¤@¨Ç¤´»Ý­n°Êª«¸ÕÅç½T»{¦w¥þ©Êªº­ì®Æ©Î²£«~¶i¤J¼Ú·ù¥«³õ¡A·íµM¼t°Ó¥i¥H³]ªk¥u¨Ï¥Î¤wª¾¤ÑµMµL¬rªº§÷®Æ¥hµÑ¨ú­ì®Æ»P»s³y¤ÆùÛ«~¡C¥t¤@¤è­±¡A¦bÂåÀø¨Ï¥Îªº²³¦hÃÄ«~¸ò§÷®Æ¡A§Y¨Ï¼Ú·ù¦a°Ï¤´¨S¦³¨î©wªk³W¸T¥Î°Êª«¸ÕÅç¤èªk¶i¦æ­ì®Æ»P¦¨«~¦w¥þ©Ê´ú¸Õ¡CÂåÃÄ»PÂåÀø¾¹§÷¼t°Ó¬O¥H¦ÛÄ@¤è¦¡¡A±Ä¥Î´X¶µ´À¥N¤è®×¶i¦æ³¡¤À¨ú¥N¦w¥þ©Ê´ú¸Õªº°Êª«¸ÕÅç¡C§Ú°ê¥ßªk°|¦b105¦~10¤ë21¤é¤TŪ³q¹L¡u¤ÆùÛ«~½Ã¥ÍºÞ²z±ø¨Ò¡v­×¥¿®×¡A­×§ï¤F²Ä23-2±ø±ø¤å¬°¡u¤ÆùÛ«~»s³y¡B¿é¤J©Î³c½æ·~ªÌ©ó°ê¤º¶i¦æ¤ÆùÛ«~©Î¤ÆùÛ«~¦¨¤À¤§¦w¥þ©Êµû¦ô¡A°£¦³¤U¦C±¡§Î¤§¤@¡A¨Ã¸g¤¤¥¡¥DºÞ¾÷Ãö³\¥iªÌ¥~¡A¤£±o¥H°Êª«§@¬°ÀË´ú¹ï¶H¡G¤@¡B¸Ó¦¨¤À³Q¼sªx¨Ï¥Î¡A¥B¨ä¥\¯àµLªk¥H¨ä¥L¦¨¤À´À¥N¡C¤G¡B¨ãµû¦ô¸ê®ÆÅã¥Ü¦³·l®`¤HÅé°·±d¤§¸·¡A¶·¶i¦æ°Êª«¸ÕÅçªÌ¡C¹H¤Ï«e¶µ³W©w¤§¤ÆùÛ«~¡A¤£±o³c½æ¡C²Ä¤@¶µ¥H°Êª«§@¬°ÀË´ú¹ï¶H¤§¥Ó½Ðµ{§Ç¤Î¨ä¥LÀ³¿í¦æ¨Æ¶µ¤§¿ìªk¡A¥Ñ¤¤¥¡¥DºÞ¾÷Ãö©w¤§¡C¡v¡A¨Ã¥B³W©w­×¥¿±ø¤å¤½¥¬¤T¦~¤§«á¤]´N¬O109¦~¶}©l¬I¦æ¡C

¹êÅç°Êª«¨Ï¥Î©ó¥Í²£ªº´À¥N¤è®×

¹êÅç°Êª«¨Ï¥Î©ó¥Í²£ªºÀ³¥Î¥]§t¬Ì­]¡B§ÜÅé¡B¾¹©x²¾´Óµ¥¡C¬Ì­]¥Í²£¨Ò¦p±N®z¤Æªº½Þ½E¯f¬rª`®g¤J¨ß¤lÅ餺¡AÅý¨ß¤l·P¬V«á³sÄòÄ~¥N¶W¹L800¦h¦¸½ü°j¤§«á±N´Ý¦s©ó¨ß¤lÅ餺ªº½Þ½E¯f¬rªº¬r©Ê­°¨ì³Ì§C¡A³Ì«áÄ묹¨ß¤l±Ä¤UµÊŦ¤Î²O¤Úµ²¤ÀÂ÷¥X¹¥¤Æ¯f¬r°µ¦¨¬Ì­]¡C²{¦b¤w¸g¦³¨Ï¥Î°ò¦]Âà´Þ¤è¦¡±N¥i¥H¨ë¿E½Þ²£¥Í§ÜÅ骺E2°ò¦]³z¹L©øÂβӭM²Õ´°ö¾i©ÎªÌª½±µ¨Ï¥Î°ò¦]Âà´ÞÅú¥hªí²{§Ü­ì³J¥Õ½è»s¦¨¬Ì­]¡A§K°£¨Ï¥Î¬¡Åé¨ß¤l»s³y½Þ½E¬Ì­]ªº»Ý¨D¡C¥Ø«e³D¬r¡BÃȬr¡B»jµï¬r¦å²M¤´¤j¦h¼Æ¨Ï¥Î°¨¤Ç¥Í²£¡Aªñ¦~¤w¸g¶}©l¦³¬ì¾Ç®a§Q¥Î°ò¦]­«²Õ¤è¦¡¦bÅé¥~²Ó­M°ö¾i¨t²Î¶i¦æ³D¬r¡BÃȬr¡B»jµï¬r§ÜÅ骺¥Í²£§Þ³N¶}µo(Alvarenga et al., 2014)¡A±N¨Ó¦³¦¨¼ôªº§Þ³N´N¥i¥H§K°£°¨¤Ç¨Ï¥Î¡C²{¦b¦³¨Ï¥Î²Ó­MÅé¥~°ö¾i¤è¦¡¡A¥i¥H¥Í²£¤H¤u¥Ö½§¡A¦p¦¹¥i¥H§K°£Ä묹½Þ¨Ó¨ú±oÂåÀø¥Îªº´À¥N¥Ö½§¡C§ó½ÆÂøªº¾¹©x³z¹LÅé¥~°ö¾i¼Ò¦¡ªº¥Í²£§Þ³N¡A¥Ø«e¤´¬O¬ì¾Ç®a¿n·¥§V¤Oªº¥Ø¼Ð¡C

¹êÅç°Êª«¨Ï¥Î©ó±Ð¾Çªº´À¥N¤è®×

§Ú°ê°Êª««OÅ@ªk©ú¤å³W©w¡u°ª¯Å¤¤µ¥¥H¤U¾Ç®Õ¤£±o¶i¦æ¥DºÞ±Ð¨|¦æ¬F¾÷Ãö©Ò©w½Òµ{ºõ­n¥H¥~¡A¨¬¥H¨Ï°Êª«¨ü¶Ë®`©Î¦º¤`¤§±Ð¾Ç°V½m¡v¡A¦]¦¹°ª¯Å¤¤µ¥¥H¤U¾Ç®Õµ´¹ï¬O»Ý­n°Êª«¨Ï¥Î©ó±Ð¾Çªº´À¥N¤è®×¡C¦ý¬O¡A¤¤µØ¥Á°êÃöÃh¥Í©R¨ó·|¦b2016½Õ¬dµo²{¡A¤´¦³°ª¤¤¦bªÀ¹Î¡BÀ綤¡B¤~ÃÀ¯Z¶i¦æ¬¡Åé°Êª«¸Ñ­å¡A³o¬O©úÅã¹Hªk¦æ¬°¡CÁöµMªk³W¨S¦³¸T¤î¤j±M°|®Õªº±Ð¾Ç¨Ï¥Î°Êª«¡A¦ý¬O¦³¤@¨Ç°ò¦½Òµ{¨Ò¦p´¶³q°Êª«¾Ç¡B¥Íª«¾Ç¡B¸Ñ­å¥Í²zªº³¡¤À±Ð®×¡A°ò¥»¤W¨S¦³¥²­n¨C¤@¦~©T©wÄ묹¤@§å¤S¤@§åªº«Cµì©Î¤p¹«¡A¥u¬°¤FÅý¾Ç¥Í¬Ý¨ì°Êª«Å餺ªººc³y¥H¤Î³¡¤À¾¹©xªº¹B§@¼Ò¦¡¡C²{¦b¦³°ê»Ú©Ê¤H¹D±Ð¨|ºô¯¸¨Ò¦p°ê»Ú¤H¹D±Ð¨|Ápºô¡]International Network for Humane Education;InterNICHE¡^¡A¸Ó²Õ´­P¤O©ó±À¼sÂå¾Ç¡BÃ~Âå¾Ç¤Î¥Íª«¬ì¾Ç¤§°ª«~½è¥B²Å¦X¤H¹Dºë¯«ªº±Ð¨|©M°V½m¡A¨Ã¥B´£¨Ñ¥ý¶iªº¬ì¾Ç±Ð¾Ç¤Î°Êª«¹êÅç´À¥N¤è®×¡A»P¦Ñ®v¦X§@¤¶²Ð°Êª«¹êÅç´À¥N±Ð¾Ç¡A¤]¤ä«ù¾Ç¥Í¦Û¥Ñ¿ï¾Ü¬O§_¾Þ§@°Êª«¹êÅ窺Åv¤O¡C

InterNICHE ºô¯¸¤W¦³´£¨Ñ¥@¬É¦U¦a³c°â±m¦â3D¼v­µ±Ð¾Ç¤ùªº»s§@¼t°ÓÁpµ¸ºô§}¥H¤Î±Ð¾Ç¤ùªº»ù®æ»P¤º®e²¤¶¡A¤è«K´M§ä±Ð§÷ªº±Ð¾Ç³æ¦ì§Ö³t§ä¨ì¤j¹«¡B«Cµì¡B½Þ¡B¤û¡B°¨¡B¤ü¡B¿ß¡B¤Hµ¥°Êª«ªº¸Ñ­å±m¦â3D³zµø¼v­µ±Ð¾Ç¤ù¡A¬Æ¦ÜÁÙ¦³°V½m¥~¬ì¤â³N¼ÒÀÀ¦Ù¦×¥Ö½§»P¦åºÞÁ_¦Xªº±Ð¾Ç°V½m¼Ò¨ã¡C¤¤µØ¥Á°êÃöÃh¥Í©R¨ó·|¬OInterNICHE»OÆW¦a°Ï¦X§@¹Ù¦ñ¡AÀ°¦£°µºô¯¸¤¤Ä¶¡AÅý²ßºD¨Ï¥Î¤¤¤åªº¤H¤h¤è«K¨Ï¥Îºô¯¸¸ê·½¡C

®Ñ­±ªº´À¥N©Ê±Ð§÷»P¨ÑÀ³°Óªº¸ê®Æ¡A¤]¥i¥H±qJukesand Chiuia (2006)½sµÛªº540­¶¯È¥»©Î¹q¤l®Ñ½¾\¬d¸ß¡C­ì«h¤W¤£½×¿ï¾Ü¨º¤@ºØ°Êª«·í¬°±Â½Ò¥DÅé¡A¨C¤@ºØ²Õ´©Î¾¹©xªº¸Ñ­åºc³y´X¥G³£¥i¥H±q¼v­µ±Ð¾Ç¤ù§ä¨ìº}«G²M·¡ªº3D¹Ï¤ù­«½Æ¨Ï¥Î¡C®Ú¾Ú§@ªÌªº²Î­p¡A¦b­^°ê¦]¬°¨Ï¥Î´À¥N©Ê±Ð§÷¡A¨Ï±o±Ð¾Ç¬°¥Øªºªº¬¡Åé°Êª«¤â³N¾Þ§@¦¸¼Æ±q1991¦~ªº12,000¦¸­°¨ì2001¦~ªº3,760¦¸¡A10¦~±À¼s´Á¶¡´N´î¤Ö¤F2/3¬¡Åé°Êª«¤â³N¾Þ§@¡C³o¤@¤è­±§i¶D§Ú­Ì¡A³Q¶}µo¥X¨Óªº´À¥N©Ê±Ð§÷½T¹ê¬O¦X¥Îªº¨Ã¥B¦³«Ü¦¨¥\ªº¼sªx±µ¨ü«×¡A¥t¤@¤è­±¤]´£¿ô§Ú­Ì³oºØ´À¥N±Ð§÷ªº¨Ï¥Î»Ý­n«Å¶Ç»P±À¼s¡A¤~·|µo¥Í§@¥Î¡CÁöµM§Ú­Ì°ê¤ºÁÙ¨S¦³«Ü¦nªº´À¥N¤è®×¥­¥x¨Ñ°ê¤H¨Ï¥Î¡A¦ý¬O¥u­n§Ú­Ì§V¤O´M§ä¡AÁÙ¬O¥i¥H§ä¨ì°ê¥~«Ü¦nªº¸ê°T¥­¥x¥i¥H´£¨Ñ¦³¥Îªº¸ê°T¡A¹³¬O®¿«Âªº°ê®a¦@ÃÑ¥­¥xºô¯¸¡A¤]´£¨Ñ¦h¤¸´À¥N±Ð§÷¸ê®Æ®wªº¬d¸ß»P³sµ²¡A¦P¤@¥­¥x¤]´£¨Ñ¬ã¨s»P°Ó«~ÀËÅ窺´À¥N©Ê¤è®×¸ê®Æ®w³sµ²¡C

µ²»y

´L­«¥Í©R­n±q±Ð¨|°µ°_¡A±q¾Ç®Õªº±Ð¾Ç½Òµ{¦w±Æ¥H¤Î´L­«¥Í©R¬°¥XµoÂIªº±Ð§÷¨Ï¥Î¡A¤~¦³¾÷·|±q¤p¶}©l°ö¾i¥¿­±ªº´L­«¥Í©R­Û²zÆ[©À¡C¦A±q¥Í¬¡¼h­±±Ð¾É¥Á²³»P»s³y¼t°Ó¡A¦p¦óÁקK¤£¥²­nªº¬¡Åé°Êª«¨Ï¥Î©ó²£«~¥Í²£»P²£«~ÀËÅç¡C¦b¬ã¨s¼h­±¡A¤]­n§V¤O¹ªÀy¨Ï¥Î´À¥N©Ê¼Ò²Õ¡A¬Æ¦Ü¤@°_§ë¤J§V¤O¬ãµo§ó¦hºØ¥\¯à©Ê§ó±jªº´À¥N©Ê¼Ò²Õ¡A³yºÖ«áÄò¬ì¾ÇÀ³¥Î°Ñ»PªÌ¡C¯à°÷±q±Ð¨|»P¦æ°Ê¤º¤Æªº¹êÅç°Êª«´À¥N²z©À¡A¤~¬O³Ì±j¦Ó¥B¦³·P¬V¤Oªº¡C

 

°Ñ¦Ò¤åÄm

¤¤µØ¥Á°êÃöÃh¥Í©R¨ó·|¡C2016¡C¡u¦b±Ð¨|¤¤¬Ý¨£°Êª«ºÖ¬ç¢w°Êª«¹êÅç´À¥N¤è®×¡v¡C¡]http://www.lca.org.tw/publish/6264¡^

Akhtar, A. 2015. The flaws and human harms of animalexperimentation. Cambridge Quarterly of Healthcare Ethics24:407–419.

Alvarenga, L. M., M. Zahid, A. di Tommaso, M. O. Juste, N. Aubrey, P. Billiald  and J. Muzard. 2014. Engineering venom’s toxin-neutralizing antibody fragmentsand its therapeutic potential. Toxins6:2541-2567.

Bailey, J., M. Thew and M. Balls. 2015. Predicting human drug toxicity and safety via animal tests: can any one species predict drug toxicity in any other, and do monkeys help?ATLA 43:393–403.

Balcombe, J. P., N. D. Barnard and C. Sandusky. 2004. Laboratory routine cause animal stress. Contemporary Topics in Laboratory Animal Science 43:42-51.

Dance, A. 2015. News Feature: Building benchtophuman models. PNAS 112:6773–6775.

Fatehullah, A., S. H. Tan and N. Barker. 2016. Organoids as an in vitro model of human development and disease. Nature Cell Biology 18:246-254.

Gibbons, D. L. and J. Spencer. 2011.Mouse and human intestinal immunity: sameballpark, different players; different rules,same score. Mucosal Immunology 4:148-157.

Hartung, T. 2013. Food for thought look back in anger–What clinical studies tell us about preclinical work. ALTEX30:275-291.

Jukes, N. and M. Chiuia. 2006. From guinea pig to computer mouse alternative methods for a progressive, humane education. 2nd edition Published by the International Network for Humane Education (InterNICHE).

Land, S., S. A. Niederer, W. E. Louch, O. M. Sejersted, and N. P. Smith. 2013 Integratingmulti-scale data to create a virtual physiologicalmouse heart. Interface Focus 3:20120076. (http://dx.doi.org/10.1098/rsfs.2012.0076)

Olson, H., G. Betton, D. Robinson, K. Thomas, A.Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes, W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger, and A. Heller. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 32:56–67.




§@ªÌ¡n ÃöÃh¥Í©R¨ó·|

¥Á°ê¤K¤Q¤@¦~ªì¡A¥Ñ¦¹¡u®À³½¡v¦]½t¡A¦³¤ß¤§¤h¥þ¤O¦¨¥ß²Õ´¡A¦³­p¹º¦a§@ªø´Á©Êªº±Ð¨|«Å¾É¡A§â¡u·RÅ@¥ÍÆF¡A¬Ã±¤ª«©R¡vªºÆ[©À²`´Ó¤H¤ß¡C©ó¬O¼ö¤ßÅTÀ³¨Ã¦¨¥ß¡uÃöÃh¥Í©R¨ó·|¡v¡C

¸Ô²Ó¤¶²Ð...

¡°¥H¤W¤å³¹¯ÂÄݧ@ªÌ¨£¸Ñ¡A«D¥»¯¸¥ß³õ

 

¬ÛÃö¤å³¹¡G

ÀH¾÷¤å³¹¡G

¡@ ¡@ ¦^¤W¤@­¶ ¦^¤W¤@­¶
¯d¨¥¤º®e(500¦r¥H¤º)(¿é¤J0¦r¡A³Ñ¾l 500¦r)

½Ðµy­Ô...

«Øij¨Ï¥ÎIE7.0¥H¤W, FireFox 3.0¥H¤W, ChromªºÂsÄý¾¹¡AÂsø°¼Ò¦¡1024x768
¥»ºô¯¸¤º®e¡B¹Ï®×¡BµÛ§@Åv ¤Î³d¥ôÂk§@ªÌ©Ò¦³¡A¸T¤î¥¼¸g±ÂÅvÂà¶K¸`¿ý¨Ï¥Î
© 1997-2024 suiis|¯À©ö All Rights Reserved.